Abstracts tagged "Pediatric rheumatology"

Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 0829 • ACR Convergence 2024
Epstein-Barr Virus Infection Triggers Hyperinflammation and Cytokine Storm in Healthy Children
Kailey Brodeur¹, Meng Liu², Rachel Weng², Evan Hsu², Lauren Henderson³, Fatma Dedeoglu², Jane Newburger³, Peter Nigrovic⁴, Mary Beth Son⁴ and Pui Lee⁵, ¹Boston Children's Hospital, Cumberland, RI, ²Boston Children's Hospital, Boston, MA, ³Boston Children's Hospital, Watertown, MA, ⁴Boston Children's Hospital, Brookline, MA, ⁵Boston Children's Hospital, Newton, MA
Background/Purpose: Epstein-Barr virus (EBV) is common pathogen responsible for infectious mononucleosis but also triggers hemophagocytic lymphohistiocytosis (HLH). This variation in the immune response to EBV…
Abstract Number: 1262 • ACR Convergence 2024
The Relationship Between Child Opportunity Index and Burden of Pediatric Systemic Lupus Erythematosus
Ayah Eltoum¹, Livie Timmerman², Melissa Mannion¹ and Emily Smitherman¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Gardendale, AL
Background/Purpose: Outcomes for systemic lupus erythematosus are known to be associated with sociodemographic indicators. The Child Opportunity Index (COI) is a well-validated measure of neighborhood…
Abstract Number: 1279 • ACR Convergence 2024
Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes
Ekemini Ogbu¹, Jareen Meinzen-Derr², Michael Wagner², Rashmi Sahay², Dhriti Sharma², J Michael Taylor², Sudhakar Vadivelu³, Mekibib Altaye² and hermine brunner¹, ¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Cerebrovascular accidents (CVA) are one of the most devastating neurologic manifestations of childhood-onset systemic lupus erythematosus (cSLE). The spectrum of CVA in cSLE (CVAcSLE)…
Abstract Number: 1765 • ACR Convergence 2024
CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling
Susan Canny¹, Hannah DeBerg², Griffin Gessay², Ailing Lu³, Mary Eckert⁴, Andrea La Bella⁵, Hayley Waterman², Danish Nadeem², Susan Shenoi⁶, Joyce Hui-Yuen⁷, Daniel Campbell², Betsy Barnes⁸ and Jessica Hamerman², ¹University of Washington, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Northwell Health, Manhasset, NY, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Cohen Children's Medical Center, Queens, NY, ⁶Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁷North Shore LIJ Health System, Great Neck, NY, ⁸Feinstein Institutes for Medical Science, Manhasset, NY
Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
Abstract Number: 1918 • ACR Convergence 2024
Exploring the Childhood Opportunity Index and Distance to Care in a Cohort of Children with Rheumatic Disease
Kristina Ciaglia¹ and Alaina Beauchamp², ¹UT Southwestern Medical Center and Scottish Rite for Children, Dallas, TX, ²UT Southwestern Medical Center, Dallas
Background/Purpose: Children from disadvantaged neighborhoods and socioeconomic backgrounds experience worse outcomes and delays in care.¹ The Childhood Opportunity Index (COI) is a multidimensional validated tool…
Abstract Number: 2186 • ACR Convergence 2024
The Exploration of Secondary Amplified Musculoskeletal Pain Syndrome (AMPS) in Pediatric Patients with Rheumatologic Disease
Sarah Ruthen¹, Mackenzie McGill¹, Nellie P Butler¹, Dori Abel¹, Melissa Argraves² and Sabrina Gmuca¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Nationwide Children's Hospital, Columbus, OH
Background/Purpose: The American College of Rheumatology defines amplified musculoskeletal pain syndrome (AMPS) as the umbrella term for non-inflammatory musculoskeletal pain, and most commonly occurs in…
Abstract Number: 2204 • ACR Convergence 2024
Guidance for Stem Cell Therapy for Juvenile Systemic Sclerosis Patients
Ivan Foeldvari¹, Kathryn Torok², Juliana Silva³, Paulina Horvei⁴, Christopher Denton⁵, Franziksa Rosser⁶, Tamas Constantin⁷, Patricia Costa Reis⁸, Megan Curran⁹, Maurizio Cutolo¹⁰, Joerg Henes¹¹, Bernd Hinrichs¹², Kim Fligelstone¹³, Suzanne Li¹⁴, Susan Maillard³, Pia Moinzadeh¹⁵, Catherine Orteu¹⁶, Clare Pain¹⁷, Clarissa Pilkington¹⁸, Linda Schraven¹⁹ and vanessa smith²⁰, ¹Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ²Division of Rheumatology, Scleroderma Center, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ³Great Ormond Street Hospital, London, United Kingdom, ⁴Division of Blood and Marrow Transplantation and Cellular Therapies, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, ⁵University College London, Northwood, United Kingdom, ⁶Division of Pulmonology Medicine, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ⁷Semmelweis University, Budapest, Hungary, ⁸Hospital de Santa Maria, Lisbon, Portugal, ⁹Children's Hospital Colorado, Colorado, ¹⁰Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ¹¹University Hospital Tuebingen, Tuebingen, Germany, ¹²Children's pulmonology, Asklepios Klinik Nord – Heidberg, Hamburg, Germany, ¹³FESCA, London, United Kingdom, ¹⁴Hackensack University Medical Center, Hackensack, ¹⁵University Hospital Cologne, Cologne, Germany, ¹⁶Royal Free London NHS Foundation Trust, London, United Kingdom, ¹⁷Alder Hey Children’s Foundation NHS Trust, Liverpool, United Kingdom, ¹⁸Great Ormond Street Hospital, London, United Kingdom, ¹⁹Dutch representative of Fesca, London, United Kingdom, ²⁰Ghent University Hospital, Gent, Belgium
Background/Purpose: Hemopoetic stem cell transplantation(HSTC) and cellular therapies(CT) are a promising therapeutic options for juvenile systemic sclerosis(jSSc) patients. As pediatric patients have a unique potential…
Abstract Number: 2618 • ACR Convergence 2024
Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Danielle Bullock⁷, Jon Burnham⁸, Tzielan Lee⁹, Daniel Lovell¹⁰, Ted Wimmel¹¹, Delores Mincarelli¹¹, Mayur Patil¹², Magen Phillips¹¹ and Esi Morgan¹³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷M Health Fairview Masonic Children’s Hospital, Minneapolis, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Hive Networks, Newport, ¹²VSquare Infotech Inc, Edison, NJ, ¹³Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
Abstract Number: 0117 • ACR Convergence 2024
Validation of the 2023 American College of Rheumatology/European League Against Rheumatism Antiphospholipid Syndrome Classification Criteria in the Pediatric Population
Daniel Bar¹, Stanley Niznik², Shiri Spielman³, Rotem Semo-Oz⁴, Assaf Barg³, Sarina Levy-Mendelovich³, Gili Kenet², Nancy Agmon- Levin² and Irit Tirosh⁵, ¹Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, HaMerkaz, Israel, ²Sheba Medical Center, Tel Aviv, Israel, ³Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Tel Aviv, Israel, ⁴Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Herzliya, Israel, ⁵Edmond and Lilly Safra Children's Hospital, Sheba Medical Center, Savyon, Israel
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial, venous or microvascular thrombosis, obstetric morbidity and/or non-thrombotic manifestations. The 2023 ACR/EULAR APS…
Abstract Number: 0395 • ACR Convergence 2024
Assessment of Enthesitis by Pediatric Rheumatology Providers
Erin Treemarcki¹, Shirley Tse², Marisa Klein-Gitelman³, Adam Mayer⁴, Hemalatha Srinivasalu⁵, Heather Walters⁶ and Melissa Oliver⁷, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, ¹University of Utah, Salt Lake City, UT, ²SickKids, Toronto, ON, Canada, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's National Hospital, Washington, DC, ⁶Northwell Health, New Hyde Park, NY, ⁷Indiana University, Indianapolis, IN
Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
Abstract Number: 0830 • ACR Convergence 2024
Activation of Autoreactive Lymphocytes in the Lung by STING Gain-of-function Mutation Expressing Radioresistant Cells
Kevin Gao¹, Kristy Chiang¹, Sharon Subramanian¹, Xihui Yin², Paul Utz³, Kerstin Nundel¹, Katherine A. Fitzgerald⁴ and Ann Marshak-Rothstein¹, ¹UMass Chan Medical School, Worcester, MA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴UMass Chan Medical School, Worchester, MA
Background/Purpose: Gain-of-function mutations in STING, a critical mediator of dsDNA sensing, lead to a severe autoinflammatory syndrome known as STING-Associated Vasculopathy with onset in Infancy…
Abstract Number: 1263 • ACR Convergence 2024
Assessing Lupus Low Disease Activity State in the Pediatric Rheumatology Clinic: Baseline Data Collection from a Pediatric Lupus Collaborative
Emily Smitherman¹, Julia Harris², Aimee Hersh³, Jennifer Huggins⁴, Ashley Lytch⁵, Hanh Ho⁶, Ashley Meyer⁷, Megan Quinlan-Waters⁴, Livie Timmerman⁸ and Jon Burnham⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Children's Mercy Kansas City, Overland Park, KS, ³University of Utah, Salt Lake City, UT, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Children's Mercy Hospital, Kansas City, MO, ⁶Children's Mercy Kansas City, Kansas City, ⁷Children's Hospital of Philadelphia, Philadelphia, ⁸University of Alabama at Birmingham, Gardendale, AL, ⁹Children's Hospital of Philadelphia, Bryn Mawr, PA
Background/Purpose: Achievement of a lupus low disease activity state (LLDAS) has been associated with less organ damage, fewer disease flares, and improved health-related quality of…
Abstract Number: 1281 • ACR Convergence 2024
The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country
Beatriz Carneiro¹, Adriana Elias², Claudia Saad-Magalhaes³, Erick Kill², Sylvia Farhat², Teresa Robazzi⁴, Ana Julia Moraes⁵, Sheila Oliveira⁶, Luciana Carvalho⁷, Taciana Fernandes³, Carlos Rabello⁸, Maria Teresa Terreri⁹, Silvana Sacchetti¹⁰, Simone Appenzeller¹¹, Clovis Silva¹², Claudio Len¹³, Darcisio Antonio¹⁴, Iloite Scheibel¹⁵, Melissa Fraga¹⁶, Marcia Bandeira¹⁷, Andre Cavalcante¹⁸, Ana Paula Vecchi¹⁹, Roberto Marini²⁰, Flavio Sztajnbok²¹, Nadia Aikawa²², lucia Maria Campos², Katia Kozu² and Maria Paula Ribeiro², ¹University of São Paulo, São Paulo, SP, Brazil, ²University of Sao Paulo, São Paulo, SP, ³São Paulo State University, Botucatu, ⁴University of Bahia, Salvador, ⁵Para Federal University, Belém do Pará, ⁶Rio de Janeiro Federal University, Rio de Janeiro, Brazil, ⁷University of São Paulo (Ribeirao Preto), Ribeirao Preto, ⁸Albert Sabin Children's Hospital, Fortaleza, ⁹UNIFESP, São Paulo, SP, Brazil, ¹⁰Santa Casa Medical School, São Paulo, SP, Brazil, ¹¹Unicamp, Campinas, SP, Brazil, ¹²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ¹³Federal University of Sao Paulo, São Paulo, SP, ¹⁴São Paulo State University, Botucatu, SP, Brazil, ¹⁵Conceição's Hospital of Porto Alegre, Porto Alegre, ¹⁶Universidade Federal de São Paulo, São Paulo, SP, Brazil, ¹⁷Pequeno Principe Hospital, Curitiba, ¹⁸Pernambuco Federal University, Recife, ¹⁹Children's Hospital of Goiania, Goiânia, ²⁰Campinas State University, Campinas, ²¹UFRJ/UERJ, SAO PAULO, Brazil, ²²Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…
Abstract Number: 1766 • ACR Convergence 2024
STAT2-Associated Type I Interferonopathy: A Masquerade of Infectious Susceptibility
Conor Gruber¹, Angelica Lee², Sofija Buta², Marta Martin Fernandez², Veronique Houdouin³, Jean-Laurent Casanova⁴, Alice Hadchouel⁵, Jacinta Bustamante⁵ and Dusan Bogunovic², ¹Mount Sinai Hospital, New York, NY, ²Columbia University, New York, NY, ³Robert Debré Hospital, Paris, France, ⁴Rockefeller University, New York, NY, ⁵Hôpital Necker-Enfants Malades, Paris, France
Background/Purpose: Type I IFN (IFN-I) signaling is a potent inflammatory pathway fundamental to antiviral immunity. In humans, loss of IFN-I activity underlies severe viral disease,…

1
2
3
…
52
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].